ADAMTS13 and thrombotic thrombocytopenic purpura: Forty-one of the full texts reviewed were excluded on the basis of confounding clinical scenarios of transplant association, CI use, or both, and no ADAMTS13 activity reported – suggesting the possibility of transplant-associated or drug-induced TMA distinct from alemtuzumab-induced secondary TTP.